Developmental safety of nirmatrelvir in zebrafish ( Danio rerio ) embryos
Birth Defects Research · 2023-03 · 115 (4) · 430-440
DOI: 10.1002/bdr2.2128 ↗At a glance
Journal article in Birth Defects Research, published online on 2022-11-14. Written by Daniela Zizioli and 6 co-authors. Institution: Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. Major MEDLINE topics: COVID-19, Water Pollutants, Chemical. Cited 16 times so far (Crossref); 27 references. Funded by: University of Brescia, University of Brescia Fondi, Università degli Studi di Brescia.
Abstract (original language)
Background
Nirmatrelvir, in combination with ritonavir, is one of the first orally available antiviral treatment for coronavirus disease 2019 (COVID‐19). Symptomatic pregnant women are at increased risk for severe illness and complications that can affect the developing baby. No malformations or lower embryo‐fetal survival have been observed when nirmatrelvir were administered to pregnant rats and rabbits. Safety evaluation of drugs used for treating COVID‐19 also in pregnancy is urgent for public health, then in this study we further investigated nirmatrelvir developmental toxicity using zebrafish as in vivo model. Material and Methods Using the standardized Fish Embryo Toxicity (FET) test, we first determined the lethal concentration 50 (LC50), exposing embryos from gastrula stage up to 120 hr post fertilization (hpf) and daily recording lethality. Then, we exposed embryos to five doses comprising the human therapeutic one and up to the LC50 (25 μM). Morphology was evaluated at 72 and 120 hpf.
Results
Nirmatrelvir did not affect survival rate and did not induce morphological defects up to the human therapeutic dose. Exposure at higher doses (2.4× and 3× the human C max ) however resulted in decreased hatching rate, reduced growth, slower heartbeat with pericardial edema, reduction of eye dimension, absence of the swim bladder and disruption of the anterior–posterior axis, with lack of tail detachment, spinal curvature and straight and smaller head.
Conclusions
Our findings in zebrafish embryos add further information about developmental nirmatrelvir safety. Further studies are needed for pharmacological safety assessment of nirmatrelvir exposure during pregnancy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
- Division of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy.
- Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
- Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy.
ORCID profiles: Daniela Zizioli, Francesco Castelli, Isabella Zanella, Eugenia Quiros-Roldan
Funding
- University of Brescia
- University of Brescia Fondi
- Università degli Studi di Brescia
Cite
APA
Zizioli, D., Ferretti, S., Mignani, L., Castelli, F., Tiecco, G., Zanella, I., & Quiros-Roldan, E. (2023). Developmental safety of nirmatrelvir in zebrafish ( Danio rerio ) embryos. Birth Defects Research, 115(4), 430-440. https://doi.org/10.1002/bdr2.2128
Vancouver
Zizioli D, Ferretti S, Mignani L, Castelli F, Tiecco G, Zanella I, et al. Developmental safety of nirmatrelvir in zebrafish ( Danio rerio ) embryos. Birth Defects Research. 2023;115(4):430-440. doi:10.1002/bdr2.2128
BibTeX
@article{Zizioli2023,
author = {Zizioli, Daniela and Ferretti, Sara and Mignani, Luca and Castelli, Francesco and Tiecco, Giorgio and Zanella, Isabella and Quiros-Roldan, Eugenia},
title = {Developmental safety of nirmatrelvir in zebrafish ( Danio rerio ) embryos},
journal = {Birth Defects Research},
year = {2023},
volume = {115},
number = {4},
pages = {430--440},
doi = {10.1002/bdr2.2128}
}
EUVIMED